|
Fonturacetam (INN; also known as phenylpiracetam, Carphedon, original trade name Phenotropil) is a phenylated analog of the drug piracetam which was developed in 1983 in Russia where it is available as a prescription drug. Research on animals has indicated that phenylpiracetam may have anti-amnesic, antidepressant, anticonvulsant, antipsychotic, anxiolytic, and memory enhancement effects.〔 ==Pharmacology== A small number of low-scale clinical studies have shown possible links between prescription of phenylpiracetam and improvement in a number of encephalopathic conditions, including lesions of cerebral blood pathways, traumatic brain injury and certain types of glioma. Phenylpiracetam reverses the depressant effects of the benzodiazepine diazepam, increases operant behavior, inhibits post-rotational nystagmus, prevents retrograde amnesia, and has anticonvulsant properties.〔 Phenylpiracetam is typically prescribed as a general stimulant or to increase tolerance to extreme temperatures and stress. In Wistar rats with gravitational cerebral ischemia, Phenylpiracetam reduced the extent of neuralgic deficiency manifestations, retained the locomotor, research, and memory functions, increased the survival rate, and lead to the favoring of local cerebral flow restoration upon the occlusion of carotid arteries to a greater extent than did piracetam. In rats, it has been found to decrease the number of nACh and NMDA receptors and increase the density of D1, D2 and D3 receptors. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Fonturacetam」の詳細全文を読む スポンサード リンク
|